Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs ABRILADA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.
Local anesthesia for infiltration, nerve block, and epidural anesthesia,Dental anesthesia,Surgical procedures requiring local anesthesia
Rheumatoid arthritis,Juvenile idiopathic arthritis,Psoriatic arthritis,Ankylosing spondylitis,Crohn's disease,Ulcerative colitis,Plaque psoriasis,Hidradenitis suppurativa,Uveitis
1-2 m L of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 m L/kg of 0.1% solution equivalent).
80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.
Alphacaine: 1.5-2 hours; epinephrine: 2-3 minutes. Clinical context: The duration of local anesthesia is prolonged by epinephrine-induced vasoconstriction, not by the half-life of alphacaine.
Terminal elimination half-life approximately 10–14 days in adults, supporting every-other-week dosing; may be shorter in pediatric patients.
Lidocaine is primarily metabolized in the liver via CYP3A4 and CYP1A2 to monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Adalimumab is a monoclonal antibody that is metabolized via catabolism into peptides and amino acids. CYP450 enzymes are not involved. No active metabolites.
Primarily renal excretion of metabolites and unchanged drug; <5% excreted unchanged in urine. Biliary excretion accounts for a minor fraction.
Primarily degraded into amino acids and recycled or excreted in urine (less than 1% unchanged); no significant biliary/fecal elimination.
Alphacaine: 55-65% bound to alpha-1-acid glycoprotein; Epinephrine: minimal binding (15-20% to albumin).
Approximately 95% bound to serum proteins, primarily alpha-1-acid glycoprotein and albumin.
Alphacaine: 1.0-1.5 L/kg, indicating extensive tissue distribution; Epinephrine: 0.2-0.4 L/kg, reflecting rapid uptake into adrenergic tissues.
Approximately 4.7–6.0 L/kg, indicating extensive distribution into tissues consistent with a monoclonal antibody.
Intravenous: 100%; Oral: negligible (high first-pass metabolism); Topical: variable (minimal systemic absorption); Local injection: essentially 100% at the site but systemic bioavailability is reduced by epinephrine.
Subcutaneous: approximately 64% (range 50–80%) absolute bioavailability relative to intravenous administration.
No specific dose adjustment required; lidocaine clearance minimally affected by renal impairment. Epinephrine use with caution if severe renal impairment due to potential vasoconstrictor effects.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use with caution.
Child-Pugh Class A: 60-80% of normal dose; Class B: 40-60% of normal dose; Class C: 20-40% of normal dose; reduce maximum single dose to 70% of standard in severe impairment.
No formal studies in hepatic impairment. Use with caution in moderate to severe impairment (Child-Pugh B or C) due to limited data.
Weight-based: 1-2 mg/kg lidocaine with epinephrine 1:100,000 (0.009-0.018 mg/kg epinephrine) for local infiltration; maximum single dose 4.5 mg/kg lidocaine (0.045 m L/kg of 1% solution).
Approved for pediatric plaque psoriasis (≥12 years): 80 mg subcutaneously every other week. For pediatric psoriatic arthritis (≥12 years): 80 mg subcutaneously every other week. For pediatric hidradenitis suppurativa (≥12 years, ≥60 kg): 160 mg on day 1, then 80 mg every other week. Pediatric Crohn's disease (≥6 years, ≥40 kg): 160 mg on day 1, then 80 mg on day 15, then 80 mg every other week; for <40 kg: 80 mg on day 1, then 40 mg on day 15, then 40 mg every other week.
Start with lowest effective dose (e.g., 0.5-1 m L of 2% lidocaine with epinephrine); reduce maximum single dose to 80% of adult maximum; monitor for cardiovascular effects of epinephrine.
No specific dose adjustment required; but monitor for infections in patients ≥65 years due to increased risk.
Not for use in obstetrical paracervical block anesthesia due to risk of fetal bradycardia and fetal death.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. SERIOUS INFECTIONS: Patients treated with adalimumab are at increased risk for serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue adalimumab if a serious infection develops. MALIGNANCY: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab.
Risk of systemic toxicity including CNS and cardiac effects,Use with caution in patients with hepatic impairment or severe renal disease,Avoid inadvertent intravascular injection,Epinephrine may cause tachycardia, hypertension, and arrhythmias,Use minimum effective dose,Monitor for signs of methemoglobinemia
Serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens,Hepatitis B virus reactivation,Hypersensitivity reactions including anaphylaxis and angioneurotic edema,Neurologic events including new onset or exacerbation of demyelinating disorders,Hematologic events including pancytopenia and aplastic anemia,Congestive heart failure,Lupus-like syndrome,Malignancies including lymphoma, leukemia, and other malignancies
Hypersensitivity to amide-type anesthetics,Severe hypotension,Concurrent use of MAO inhibitors or tricyclic antidepressants (relative),Shock,Avoid use in areas with poor blood supply
Known hypersensitivity to adalimumab or any inactive component of the product,Active serious infections including sepsis, tuberculosis, and opportunistic infections
No significant food interactions. Avoid hot liquids or food until numbness resolves to prevent oral burns.
No significant food interactions. Grapefruit and other CYP450 modulators do not affect adalimumab. Take without regard to meals.
Pregnancy category C. First trimester: Lidocaine crosses placenta; epinephrine may reduce uterine blood flow. No well-controlled human studies; animal studies show fetal harm at high doses. Second trimester: Similar risks; avoid near cervix to prevent systemic absorption. Third trimester: Placental transfer increases; risk of fetal acidosis, bradycardia, and neurobehavioral depression with high doses.
Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates exposed in utero. First trimester: Minimal known risk. Second/third trimester: May cross placenta; theoretical risk of immunosuppression.
Lidocaine and epinephrine are excreted in breast milk in low amounts. Lidocaine M/P ratio ~0.5; epinephrine M/P ratio unknown. Infant dose via milk is ~1-2% of maternal weight-adjusted dose. Risk of neonatal bradycardia or irritability is low with standard doses. Use caution with high doses or repeated administration.
Excreted in human milk in low concentrations; M/P ratio not well defined. Considered compatible with breastfeeding, but monitor infant for infection risks.
Pregnancy increases plasma volume and metabolism; no specific dose adjustments recommended for lidocaine or epinephrine. Use lowest effective dose and concentration to minimize fetal exposure. Avoid intra-arterial injection and use with caution in preeclampsia or compromised placental perfusion.
No dose adjustment routinely required; pregnancy may increase clearance, but no established guidelines for dose modification.
Alphacaine Hydrochloride w/ Epinephrine is a dental local anesthetic solution containing lidocaine HCl 2% with epinephrine 1:100,000 or 1:50,000. The epinephrine component provides vasoconstriction, prolonging anesthetic duration and reducing systemic absorption. Maximum dose of lidocaine with epinephrine is 7 mg/kg (not to exceed 500 mg). For dental infiltration, use smallest effective volume. Avoid intravascular injection; aspirate before injection. Use caution in patients with severe cardiovascular disease, hypertension, hyperthyroidism, or those on MAOIs or tricyclic antidepressants due to potential for hypertensive crisis. Epinephrine may cause tachycardia or hypertension. Do not use in patients with allergy to amide anesthetics or sulfites (present in some formulations).
ABRILADA (adalimumab) is a TNF-alpha inhibitor. Monitor for latent TB reactivation with PPD or IGRA before initiation. Injection site reactions are common; rotate sites and apply cold compresses. Avoid live vaccines during therapy. Assess for new-onset or worsening heart failure, demyelinating disorders, and cytopenias. Increased risk of serious infections; screen for HBV, HCV, and fungal infections. Consider temporarily holding therapy for major surgical procedures.
This medication is a local anesthetic used to numb a specific area in your mouth for dental procedures.,You may feel a burning sensation during injection, but numbness should set in quickly.,Avoid eating or drinking hot beverages for at least 1 hour after the procedure to prevent burns while numb.,Do not chew on the numb side until sensation returns fully.,If you experience chest pain, palpitations, severe headache, or difficulty breathing, seek emergency medical attention immediately.,Report any signs of allergic reaction such as rash, swelling, or difficulty breathing to your dentist or doctor.,Inform your dentist of all medications you take, especially MAOIs, tricyclic antidepressants, beta-blockers, or thyroid medications.,This medication contains epinephrine, which can raise heart rate and blood pressure.
Inspect injection site for redness, swelling, or itching; apply cold compress if needed.,Report signs of infection: fever, cough, painful urination, or skin wounds.,Avoid live vaccines (e.g., MMR, shingles, nasal flu) during treatment.,Review all current medications, including OTC and herbal supplements.,Notify healthcare provider before any planned surgery.,Use reliable contraception if of childbearing potential; continue 5 months after stopping.,Report new or worsening symptoms: shortness of breath, chest pain, numbness, vision changes.,Store ABRILADA in the refrigerator (36°F-46°F); do not freeze or shake.
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs ABRILADA, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is a Alpha/Beta Agonist that works by Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.. ABRILADA is a TNF-Alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE and ABRILADA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is: 1-2 m L of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 m L/kg of 0.1% solution equivalent).. The standard adult dose of ABRILADA is: 80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE and ABRILADA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is classified as Category A/B. Pregnancy category C. First trimester: Lidocaine crosses placenta; epinephrine may reduce uterine blood flow. No well-controlled human studies; animal studies show fetal harm at hi. ABRILADA is classified as Category C. Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates expose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.